BK Virus Infection
28
7
8
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.7%
3 terminated out of 28 trials
72.7%
-13.8% vs benchmark
11%
3 trials in Phase 3/4
88%
7 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (28)
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
A Study to Understand How a New, Unlicensed Drug Works, Compared With a Placebo, Against BK Virus in Patients Who Have Had a Kidney Transplant.
Immune Registry for BK in Kidney Transplant Recipients
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
TETRAVI Expanded Access Program
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
R-MVST Cells for Treatment of Viral Infections
BK With VST for Kidney Transplant Patients
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia